The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 4, 2022. Its latest SEC filing is a SC 13G/A from Feb 10, 2023.
10-Q for Q1 FY2022, filed May 4, 2022
The sections below describe the company as of the FY2021 annual report.
Sells steroid-releasing sinus implants for use after surgery and in physician offices, plus surgical navigation and balloon-dilation equipment for hospitals, surgery centers and ear, nose and throat physicians.
10-K for FY2021, filed Mar 8, 2022We are a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care. Our U.S. Food and Drug…View ↗
Our PROPEL family of steroid releasing implants are clinically proven to improve outcomes for CRS patients following sinus surgery. PROPEL…View ↗
Following sinus surgery, the underlying chronic inflammation associated with CRS can lead to recurrent obstruction of the sinus cavity over…View ↗
Our PROPEL family of products are used primarily in the operating room of a hospital or ASC. These providers receive a facility fee for the…View ↗
Our VenSure Navigable and Stand-alone balloon offerings are used to access and treat the frontal, recess sphenoid sinus ostia, maxillary…View ↗
Our CUBE Navigation System is an innovative virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The…View ↗
Hospitals and surgery centers buy PROPEL implants, with sales counted when products ship; typical payment terms are 30 to 90 days. Specialty pharmacies and distributors buy SINUVA, with sales counted when they receive it.
10-K for FY2021, filed Mar 8, 2022The Company recognizes revenue when its customer obtains control of promised goods, in an amount that reflects the consideration which the…View ↗
The PROPEL family of products are regulated by the FDA as medical devices. The Company recognizes revenue through sales of its PROPEL…View ↗
The FDA has approved SINUVA as a drug and it is therefore regulated as such. The Company sells SINUVA to a limited number of specialty…View ↗
10-K for FY2021, filed Mar 8, 2022
FY2021 revenue by product or service ↗$106.7M
10-K for FY2021, filed Mar 9, 2022
$106.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
PROPEL family of products
Sold outright
10-K for FY2021, filed Mar 8, 2022 |
85%
FY2018: 97%
|
PROPEL family of products, FY2021
$91.1M Sources
|
Sold outright |
|
SINUVA
Sold outright
|
8.5%
FY2018: 2.6%
|
SINUVA, FY2021
$9.1M Sources
|
Sold outright |
|
VenSure, CUBE, and accessories
|
6.1%
FY2018: 0.0%
|
VenSure, CUBE, and accessories, FY2021
$6.6M Sources
|
The company sells PROPEL to hospitals and surgery centers; it sells SINUVA through specialty pharmacies and distributors, which then sell it to health care providers.
10-K for FY2021, filed Mar 8, 2022
No. It lost $159.6M in FY2021.
10-K for FY2021, filed Mar 9, 2022
−$141MView ↗
10-K for FY2021, filed Mar 9, 2022
−$159.6MView ↗
10-K for FY2021, filed Mar 9, 2022
−$61.5MView ↗
10-Q for Q1 FY2022, filed May 5, 2022
−$28.8MView ↗
10-Q for Q1 FY2022, filed May 4, 2022
Open tableView ↗
8-K, filed May 13, 2022
As described in the Introductory Note, on May 13, 2022, the Merger was completed. Upon the consummation of the Merger, the Company became a…View ↗
8-K, filed Mar 23, 2022
In connection with the Merger and the FTC review process, the Company intends to divest the businesses currently operated by (i) Intersect…View ↗
Grew. Revenue grew 11% in 4 years, from $96.3M in FY2017 to $106.7M in FY2021, about 3% a year.
Expanded product range
The product range expanded beyond the steroid-releasing implants described in the older report: the latest report also covers VenSure sinus-dilation products and CUBE surgical navigation equipment acquired with Fiagon.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Mar 8, 2022We are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. Our…View ↗
We are a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care. Our U.S. Food and Drug…View ↗
Competes with Medtronic, Olympus, Johnson & Johnson, Stryker, Lyra Therapeutics, Smith & Nephew Group, OptiNose, and Regeneron Pharmaceuticals
10-K for FY2021, filed Mar 8, 2022Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of…View ↗
Loading...
